The 10-fold diluted reuterin-containing supernatant decreased <i>S.</i> Typhimurium χ3339 colonization in 3-D HT-29 aggregates, while the supernatant without reuterin stimulated χ3... by Rosemarie De Weirdt (320666)

Reduced callose synthesis in <i>pat</i> is associated with the decreased <i>CalS5</i> expression. by Shuang-Xi Xiong (8844044)

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Adaptation of <i>B</i>. <i>subtilis</i> Rho⁺ cells to a sudden nutrient downshift. by Vladimir Bidnenko (4258573)

“…<i>subtilis</i> WT, Rho⁺ and their respective derivative strains carrying <i>guaB</i>S121F and <i>guaB</i>T139I mutations were cultivated in liquid S7 medium containing 0.5% (w/v) of CAA and tested for the ability to grow in the absence of CAA as in (A). …”

RhoA-induced suppression of the HSR decreases cell stress resistance and induces cell death via apoptosis. by Roelien A. M. Meijering (217816)

Dex increases migration independently of WNT5A/Frizzled-5 interaction. by Martin Crozier (13804275)

Sirt5 KO induces increased lysine succinylation and decreased ATP synthase activity in mouse heart mitochondria. by Mengli Zhang (6331172)

Activin A decreases MPTP and LPS-induced inflammation. by Sandy Stayte (728461)

“…<p>Stereological quantification of the left SNpc demonstrated activin A significantly decreased the number of GFAP-immunoreactive cells (A) and Iba1-immunoreactive cells (B) in the SNpc following MPTP. …”

siRNA-mediated depletion of CUL5 in HUVEC prevents thalidomide-dependent decrease in cellular proliferation. by Bryan Kunkler (5204327)

Image_2_Comparison of Carrier and de novo Pathogenic Variants in a Chinese DMD/BMD Cohort.TIF by Jinfu Lin (5632655)

“…With advances in prenatal diagnosis decreasing the number of affected offspring from carrier mothers, the frequency of de novo variants could increase. …”

The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages. by Manuela Mally (348810)

Carried out substitution depending on a potential agreement. by Jean-Stephane Giraud (9421750)

Subjects:

Database resulting from the second survey. by Jean-Stephane Giraud (9421750)

Subjects:

Treatments characteristics of included patients. by Jean-Stephane Giraud (9421750)

Subjects:

Sociodemographic and clinical characteristics of the 98 PLWHA who participated in our study. by Jean-Stephane Giraud (9421750)

Subjects:

Database resulting from the first survey. by Jean-Stephane Giraud (9421750)

Subjects: